Chimerix
CMRX

$0.8756

2.2%

Market Cap: $78.5M

About: Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Employees: 72

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2.27% less ownership

Funds ownership: 43.51% [Q1] → 41.24% (-2.27%) [Q2]

8% less funds holding

Funds holding: 77 [Q1] → 71 (-6) [Q2]

21% less capital invested

Capital invested by funds: $41.2M [Q1] → $32.4M (-$8.77M) [Q2]

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

41% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 22

65% less call options, than puts

Call options by funds: $63K | Put options by funds: $178K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$11

1,156%

upside

Avg. target

$11

1,156%

upside

High target

$11

1,156%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Edward White

32% 1-year accuracy

35 / 111 met price target

1,156%upside

$11

Buy

Reiterated

14 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CMRX published over the past 30 days

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Officer Michelle LaSpaluto - Chief Financial Officer Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Soumit Roy - Jones Research Ed White - HC Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Chimerix Second Quarter 2024 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will O'Connor – Stern Investor Relations Mike Andriole – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Josh Allen – Chief Technology Officer Michelle LaSpaluto – Chief Financial Officer Tom Riga – Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft – Jefferies Naureen Quibria – Capital One Soumit Roy – Jones Research Troy Langford – TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor of Stern Investor Relations.

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 –

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Chimerix: Tackling A Strong Unmet Need With Promising Data

Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3 K27M-mutated diffuse midline glioma. The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook.

Chimerix: Tackling A Strong Unmet Need With Promising Data

See News Rankings